
June 16 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:
NEXTCURE AND SIMCERE ZAIMING ANNOUNCE STRATEGIC PARTNERSHIP FOR A NOVEL ANTIBODY-DRUG CONJUGATE TARGETING CDH6
NEXTCURE INC - GAINS GLOBAL RIGHTS TO SIM0505 EXCLUDING GREATER CHINA
NEXTCURE INC - U.S. PHASE 1 CLINICAL TRIAL FOR SIM0505 TO BEGIN Q3 2025
NEXTCURE INC - SIMCERE ZAIMING ELIGIBLE FOR PAYMENTS UP TO $745M AND ROYALTIES
NEXTCURE INC - INITIAL PHASE 1 CLINICAL DATA EXPECTED IN FIRST HALF OF 2026